Filing Flows › UroGen Pharma (URGN) › Guidance history
UroGen Pharma (URGN) guidance history: what it guided and what it reported
UroGen Pharma gave guidance in 3 earnings releases on file since May 6, 2026. Its releases raised guidance once and lowered it once.
Operating expenses
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $240M–$250M (May 6, 2026) → raised $260M–$270M (Aug 5, 2026) → reaffirmed $260M–$270M (Nov 4, 2026) | — | to be reported | — |
The latest quarter
UroGen Pharma, Q3 2026: revenue $89.0M (+224% year over year), operating margin 9.4%, net loss $1.5M, operating cash flow −$15.2M. The chart follows the revenue to costs, profit and cash.
Questions
Does UroGen Pharma beat its guidance?
UroGen Pharma gave guidance in 3 earnings releases on file since May 6, 2026. Its releases raised guidance once and lowered it once.
How often does UroGen Pharma raise guidance?
Its earnings releases raised guidance once and lowered it once since May 6, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.